Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

计划入组 27 人 · 首次发布于 2015 年 12 月 16 日

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

计划入组 300 人 · 首次发布于 2020 年 12 月 3 日

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

计划入组 2,395 人 · 首次发布于 2021 年 6 月 3 日

III-30

CI-III

Coproporphyrinogen III

C₃₆H₄₄N₄O₈

Carlos Iii Health Institute

Spain

Triphase Research and Development III Corp.

Centro Nacional de Investigaciones Oncologicas CARLOS III

FDA Unveils FY 2027 User Fee Rates: PDUFA Revenue Target Rises 6%, MDUFA Jumps 14%

FDA Launches Public Input Process for BsUFA IV Reauthorization to Shape Biosimilar Regulatory Framework Through 2032

FDA Finalizes Guidance on Alternative Inspection Tools for Drug Manufacturing Facilities